C12N 2710/24162
By genetic engineering
Official title: by genetic engineering
C12N2710/24162 (By genetic engineering) appears on 23 US grants and 39 published applications in this corpus.
Search patents in C12N- Granted patents
- 23
- Published applications
- 39
- Assignees
- 25
- Inventors
- 97
- Latest grant
- 21 Jul 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1991 | 1 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 0 | 0 |
| 1998 | 0 | 0 |
| 1999 | 1 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 1 | 0 |
| 2003 | 0 | 0 |
| 2004 | 0 | 0 |
| 2005 | 0 | 2 |
| 2006 | 1 | 2 |
| 2007 | 0 | 1 |
| 2008 | 0 | 0 |
| 2009 | 0 | 5 |
| 2010 | 0 | 0 |
| 2011 | 2 | 1 |
| 2012 | 2 | 3 |
| 2013 | 0 | 4 |
| 2014 | 2 | 3 |
| 2015 | 3 | 1 |
| 2016 | 1 | 1 |
| 2017 | 1 | 2 |
| 2018 | 1 | 1 |
| 2019 | 0 | 2 |
| 2020 | 2 | 2 |
| 2021 | 1 | 1 |
| 2022 | 2 | 4 |
| 2023 | 0 | 2 |
| 2024 | 0 | 1 |
| 2025 | 0 | 1 |
| 2026 | 2 | 0 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Oncolytic vaccinia virus21 Jul 2026US 12,686,856 B2KM Biologics Co., Ltd.
- Oncolytic vaccinia virus26 May 2026US 12,637,663 B2KM Biologics Co., Ltd.
- Recombinant vaccinia virus and use thereof27 Sep 2022US 11,452,770 B2Kolon Life Science, Inc.
- Genetically engineered vaccinia viruses31 May 2022US 11,344,589 B2Astellas Pharma Inc.
- Genetically engineered vaccinia viruses12 Jan 2021US 10,888,594 B2Astellas Pharma Inc.
- Improved vaccinia virus vectors2 Oct 2025US 2025/0302997 A1
- Use of Ectromelia Virus for Cancer Immunotherapy and Vaccines25 Jul 2024US 2024/0245765 A1Poximmunomics LLC
- Oncolytic Vaccinia Virus21 Sep 2023US 2023/0293608 A1Queen Mary University of London
- Treatment of immune depression17 Aug 2023US 2023/0256057 A1Transgene S. A.
- Pharmaceutical composition for treating cancer comprising anticancer virus, immune checkpoint inhibitor and hydroxyurea as active ingredients17 Nov 2022US 2022/0362316 A1Bionoxx Inc.
Most cited
By later US patents
- Modified vaccinia virus strains for use in diagnostic and therapeutic methods40US 8,052,968 B2Genelux Corporation · 2011
- Recombinant vaccinia viral vectors20US 6,372,455 B1Arizona Board of Regents · 2002
- Modified vaccinia virus strains for use in diagnostic and therapeutic methods20US 8,066,984 B2Genelux Corporation · 2011
- Vaccinia virus MVA-E3L-knockout-mutants and use thereof19US 7,049,145 B2GSF-Forschungszentrum fur Umwelt und Gesundheit GmbH · 2006
- Oncolytic viruses and methods for treating neoplastic disorders16US 8,679,509 B2The Governors of the University of Alberta · 2014